{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:01:09Z","timestamp":1761843669545,"version":"3.44.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":2152,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.virol.2007.05.024","type":"journal-article","created":{"date-parts":[[2007,6,28]],"date-time":"2007-06-28T09:03:25Z","timestamp":1183021405000},"page":"175-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens"],"prefix":"10.1016","volume":"367","author":[{"given":"Michael S.","family":"Seaman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F.","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren E.","family":"Grandpre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa T.","family":"Bartman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman L.","family":"Letvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Mascola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.virol.2007.05.024_bib1","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1128\/JVI.73.2.1740-1745.1999","volume":"73","author":"Beddows","year":"1999","journal-title":"J. Virol."},{"issue":"18","key":"10.1016\/j.virol.2007.05.024_bib2","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1097\/00002030-199818000-00009","article-title":"Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group","volume":"12","author":"Belshe","year":"1998","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.virol.2007.05.024_bib3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.virol.2003.12.003","article-title":"Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV","volume":"320","author":"Buckner","year":"2004","journal-title":"Virology"},{"issue":"18","key":"10.1016\/j.virol.2007.05.024_bib4","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1089\/088922200750054756","article-title":"Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1","volume":"16","author":"Bures","year":"2000","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"3","key":"10.1016\/j.virol.2007.05.024_bib40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/ni0304-233","article-title":"HIV vaccine design and the neutralizing antibody problem","volume":"5","author":"Burton","year":"2004","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.virol.2007.05.024_bib5","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.75.5.2224-2234.2001","article-title":"Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian\/human immunodeficiency virus infection in pigtailed macaques","volume":"75","author":"Cho","year":"2001","journal-title":"J. Virol."},{"issue":"7\u20138","key":"10.1016\/j.virol.2007.05.024_bib6","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0264-410X(00)00267-X","article-title":"Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein","volume":"19","author":"Coeffier","year":"2000","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.virol.2007.05.024_bib7","doi-asserted-by":"crossref","first-page":"10199","DOI":"10.1128\/JVI.73.12.10199-10207.1999","article-title":"Characterization of primary isolate-like variants of simian\u2013human immunodeficiency virus","volume":"73","author":"Crawford","year":"1999","journal-title":"J. Virol."},{"issue":"18","key":"10.1016\/j.virol.2007.05.024_bib8","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.1128\/JVI.74.18.8358-8367.2000","article-title":"Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120","volume":"74","author":"Derdeyn","year":"2000","journal-title":"J. Virol."},{"issue":"4648","key":"10.1016\/j.virol.2007.05.024_bib9","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1126\/science.6200936","article-title":"Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS","volume":"224","author":"Gallo","year":"1984","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.virol.2007.05.024_bib10","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1128\/jvi.70.3.1651-1667.1996","article-title":"Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization","volume":"70","author":"Gao","year":"1996","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2007.05.024_bib11","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1128\/JVI.79.2.1154-1163.2005","article-title":"Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein","volume":"79","author":"Gao","year":"2005","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.virol.2007.05.024_bib12","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1128\/JVI.78.11.5983-5995.2004","article-title":"Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies","volume":"78","author":"Haigwood","year":"2004","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2007.05.024_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/1568005054201517","article-title":"Application of the polyvalent approach to HIV-1 vaccine development","volume":"5","author":"Hurwitz","year":"2005","journal-title":"Curr. Drug Targets Infect. Disord."},{"issue":"23","key":"10.1016\/j.virol.2007.05.024_bib14","doi-asserted-by":"crossref","first-page":"12764","DOI":"10.1128\/JVI.77.23.12764-12772.2003","article-title":"Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines","volume":"77","author":"Kong","year":"2003","journal-title":"J. Virol."},{"issue":"14","key":"10.1016\/j.virol.2007.05.024_bib15","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.1128\/JVI.78.14.7490-7497.2004","article-title":"Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys","volume":"78","author":"Letvin","year":"2004","journal-title":"J. Virol."},{"issue":"16","key":"10.1016\/j.virol.2007.05.024_bib16","doi-asserted-by":"crossref","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","article-title":"Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies","volume":"79","author":"Li","year":"2005","journal-title":"J. Virol."},{"issue":"23","key":"10.1016\/j.virol.2007.05.024_bib17","doi-asserted-by":"crossref","first-page":"11776","DOI":"10.1128\/JVI.01730-06","article-title":"Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa","volume":"80","author":"Li","year":"2006","journal-title":"J. Virol."},{"issue":"22","key":"10.1016\/j.virol.2007.05.024_bib18","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1016\/S0264-410X(99)00125-5","article-title":"Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein","volume":"17","author":"Liang","year":"1999","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.virol.2007.05.024_bib19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.virol.2006.04.043","article-title":"A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses","volume":"353","author":"Liao","year":"2006","journal-title":"Virology"},{"issue":"8","key":"10.1016\/j.virol.2007.05.024_bib20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/088922202753747914","article-title":"HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus","volume":"18","author":"Long","year":"2002","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"3","key":"10.1016\/j.virol.2007.05.024_bib41","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/1566524033479799","article-title":"Defining the protective antibody response for HIV-1","volume":"3","author":"Mascola","year":"2003","journal-title":"Curr. Mol. Med."},{"issue":"2","key":"10.1016\/j.virol.2007.05.024_bib21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/infdis\/173.2.340","volume":"173","author":"Mascola","year":"1996","journal-title":"J. Infect. Dis."},{"issue":"16","key":"10.1016\/j.virol.2007.05.024_bib22","doi-asserted-by":"crossref","first-page":"10103","DOI":"10.1128\/JVI.79.16.10103-10107.2005","article-title":"Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines","volume":"79","author":"Mascola","year":"2005","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2007.05.024_bib23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1128\/JVI.79.2.771-779.2005","article-title":"Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins","volume":"79","author":"Mascola","year":"2005","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2007.05.024_bib42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/1568005054201580","article-title":"Antibodies: can they protect against HIV infection?","volume":"5","author":"Mc Cann","year":"2005","journal-title":"Curr. Drug Targets Infect. Disord."},{"key":"10.1016\/j.virol.2007.05.024_bib24","series-title":"Current Protocols in Immunology","first-page":"12.11.1","article-title":"Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays","author":"Montefiori","year":"2004"},{"issue":"2","key":"10.1016\/j.virol.2007.05.024_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1128\/jcm.26.2.231-235.1988","article-title":"Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay","volume":"26","author":"Montefiori","year":"1988","journal-title":"J. Clin. Microbiol."},{"issue":"2","key":"10.1016\/j.virol.2007.05.024_bib43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1568005054201535","article-title":"HIV-1: the confounding variables of virus neutralization","volume":"5","author":"Nara","year":"2005","journal-title":"Curr. Drug Targets Infect. Disord."},{"issue":"6","key":"10.1016\/j.virol.2007.05.024_bib26","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1128\/JVI.74.6.2960-2965.2000","article-title":"Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques","volume":"74","author":"Ourmanov","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2007.05.024_bib27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev.immunol.24.021605.090557","article-title":"GP120: target for neutralizing HIV-1 antibodies","volume":"24","author":"Pantophlet","year":"2006","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.virol.2007.05.024_bib28","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/JVI.72.4.2855-2864.1998","article-title":"Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1","volume":"72","author":"Platt","year":"1998","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.virol.2007.05.024_bib29","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1128\/JVI.73.7.5255-5264.1999","article-title":"Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties","volume":"73","author":"Poss","year":"1999","journal-title":"J. Virol."},{"issue":"30","key":"10.1016\/j.virol.2007.05.024_bib30","doi-asserted-by":"crossref","first-page":"11088","DOI":"10.1073\/pnas.0401954101","article-title":"Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses","volume":"101","author":"Santra","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"10","key":"10.1016\/j.virol.2007.05.024_bib31","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.4049\/jimmunol.162.10.6155","article-title":"Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera","volume":"162","author":"Scala","year":"1999","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.virol.2007.05.024_bib32","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1128\/JVI.79.5.2956-2963.2005","article-title":"Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys","volume":"79","author":"Seaman","year":"2005","journal-title":"J. Virol."},{"issue":"4679","key":"10.1016\/j.virol.2007.05.024_bib33","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1126\/science.6095449","article-title":"Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome","volume":"226","author":"Shaw","year":"1984","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.virol.2007.05.024_bib34","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.vaccine.2006.10.046","article-title":"Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs","volume":"25","author":"Shu","year":"2007","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.virol.2007.05.024_bib35","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1089\/aid.1998.14.1129","article-title":"Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication","volume":"14","author":"Stamatatos","year":"1998","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"18","key":"10.1016\/j.virol.2007.05.024_bib36","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1089\/08892220152741450","article-title":"A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1","volume":"17","author":"Stiegler","year":"2001","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"2","key":"10.1016\/j.virol.2007.05.024_bib37","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1128\/jvi.70.2.1100-1108.1996","article-title":"Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1","volume":"70","author":"Trkola","year":"1996","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.virol.2007.05.024_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.virol.2006.02.032","article-title":"Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E","volume":"350","author":"Wang","year":"2006","journal-title":"Virology"},{"issue":"46\u201347","key":"10.1016\/j.virol.2007.05.024_bib39","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1016\/j.vaccine.2005.07.008","article-title":"Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV","volume":"23","author":"Zhan","year":"2005","journal-title":"Vaccine"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682207003789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682207003789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T23:48:47Z","timestamp":1758584927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682207003789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0042682207003789"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2007.05.024","relation":{},"ISSN":["0042-6822"],"issn-type":[{"type":"print","value":"0042-6822"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2007.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}